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In this issue of Cancer Cell, Tummala and colleagues demonstrate that unconventional prefoldin RPB5 inter-
actor (URI) expression in hepatocytes leads to hepatocellular carcinoma (HCC) development by interacting
with L-tryptophan/kynurenine/nicotinamide adenine dinucleotide (NAD+) metabolism. The results suggest
that supplementation of NAD+ may be a prophylactic or therapeutic approach in HCC.Liver cancer is the fifth most common
cancer and the second leading cause of
cancer mortality, causing more than
700,000 deaths per year world-wide (Je-
mal et al., 2011). In contrast to the overall
decreasing mortality rates for most other
types of cancers, the incidence of hepato-
cellular carcinoma (HCC) in the United
States has tripled in the last two decades,
while the overall survival rate has re-
mained below 12% (El-Serag, 2011).
HCC typically develops as a long-term
consequence of chronic liver disease,
triggered most commonly by viral hepati-
tis, alcoholic liver disease, and nonalco-
holic fatty liver disease. Although HCC
can be cured at early stages, e.g., by liver
transplantation, the overwhelming major-
ity of patients are in advanced stages at
the time of diagnosis and not eligible
for curative treatment approaches. The
multi-kinase inhibitor sorafenib is effec-
tive in advanced HCC but prolongs
median survival only from 7.9 months to
10.7 months (Llovet et al., 2008).
Numerous factors, including a wide spec-
trum of genetic aberrations, resistance to
anticancer drugs, and development of
novel lesions within benign cirrhotic liver
tissue make the development of treat-
ment approaches for HCC exceedingly
difficult (Forner et al., 2012). Hence,
HCC prevention is an important strategy
that could save thousands of lives every
year. However, mechanisms that drive
carcinogenesis in chronic liver disease
remain only incompletely understood
and we therefore do not have efficient
prevention strategies besides curing the
underlying disease.In this issue of Cancer Cell, Tummala
et al. (2014) unravel a novel pathway that
links the putative oncogene unconven-
tional prefoldin RBP5 interactor (URI) and
NAD+ pools to genotoxic stress and hepa-
tocarcinogenesis. Previous studies had
demonstrated URI amplification in ovarian
cancer, resulting in increased mitochon-
drial threshold for apoptosis and
increased cell survival through inhibition
of phosphatase PP1g (Theurillat et al.,
2011). Using a tetracycline-controlled
transgenic approach, Tummala et al.
(2014) demonstrated that hepatocyte-
specific overexpression of human URI
(hURI) drives the development of
dysplasia, from low- to high-grade, and
HCCas thesemice aged, with HCCdevel-
oping between 54–75 weeks. All hURI-
overexpressingmicediedbefore85weeks
often with metastatic foci in the lung, the
most common metastatic site for HCC.
Moreover, heterozygous and homozy-
gous hURI overexpression reduced the
latency of HCC induced by the genotoxin
diethylnitrosamine (DEN) to 30 weeks
and 10 weeks, respectively. Conversely,
reducing URI expression to z50% by
hepatocyte-specific heterozygous dele-
tion of URI (URI(x/D)hep) prevented DEN-
induced HCC development. The authors
then proceeded to demonstrate that
hURI-overexpressing livers displayed
signs of DNA damage at early time
points, as apparent by increased expres-
sion of phosphorylated histone gH2AX,
accompanied by increased senescence-
associated b-galactosidase activity, p53
phosphorylation, and upregulation of
p53 transcription targets such as BAXCancer Cell 26,and p21. Moreover, concomitant p53
inactivation accelerated hURI-triggered
hepatocarcinogenesis.
Tummala et al. (2014) found that,
different from previous studies, URI acts
through a PP1g-independent pathway in
their HCCmodels. Employing global tran-
scriptomic and proteomic profiling at
stages when no tumors had yet devel-
oped, they uncovered that hURI-overex-
pression in hepatocytes downregulated
L-tryptophan/kynurenine catabolism, re-
sulting in reduced nicotinamide adenine
dinucleotide (NAD+) concentrations.
Conversely, NAD+ levels were increased
in URI(x/D)hep livers. Supplementation of
NAD+ pools via dietary nicotinamide ribo-
side in hURI-overexpressing mice not
only reduced dysplastic lesions, but also
prevented tumor development, proving
the functional relevance of NAD+ and its
dysbalance as one of the mediators of
hURI-driven carcinogenesis in the liver.
Mechanistically, the authors demon-
strated significant overlap of their tran-
scriptomic data with existing data from
aryl hydrocarbon receptor (AhR) and
estrogen receptor (ER) knockout mice
and provided strong evidence in cell lines
that AhR and ER mediate hURI-induced
transcriptional repression of L-trypto-
phan/kynurenine catabolism via regula-
tors such as TDO2 and AFMID. Of
therapeutic relevance, the authors also
demonstrated that ‘‘full blown’’ tumors in
hURI-overpressing mice regressed with
increased apoptosis when these mice
were fed with a nicotinamide riboside
diet. Furthermore, the authors found URI
to be overexpressed in human HCC andDecember 8, 2014 ª2014 Elsevier Inc. 777
Figure 1. The URI/NAD+ Pathway Can Be Targeted for the
Prevention or Treatment of HCC
Increased expression of URI in inflamed or injured liver leads to AhR- and/or
ER-mediated reduction of NAD+, leading to DNA damage, which, in turn, trig-
gers dysplasia, adenoma, and HCC development. Blocking URI, increasing
AhR or ER activity, or restoring NAD+ levels can be employed for the preven-
tion or treatment of HCC.
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Previewshigh expression to be corre-
lated with NAD+ synthesis
inhibition and poorer patient
survival.
As concomitant p53 abla-
tion increased HCC develop-
ment in hURI-overexpressing
mice despite reducing overall
cell death, the current study
highlights the concept that
genotoxic stress is a key
contributor to liver carcino-
genesis and cell death is
possibly only a second hit.
Accordingly, HCC can occur
in the absence of liver in-
flammation or cirrhosis in
patients with hepatitis B,
especially in those with
elevated HBV DNA who ac-
quired the hepatitis B virus
by vertical transmission dur-
ing birth or early childhood
(Chen et al., 2006). On the
other hand, the strong asso-ciation of parameters of cell death, such
as serum alanine aminotransferase in
patients and the development of HCC
in animal models with genetically
induced chronic cell death indicate that
chronic cell death alone may be suffi-
cient to trigger HCC (Luedde et al.,
2014). These seemingly opposite find-
ings can be explained when consider-
ing that the cellular compartment in
which cell death occurs largely dictates
the development of cancer. The death
of cells that harbor cancer-promoting
mutations reduces HCC, whereas death
of other cells may either trigger muta-
tions through inflammation and ROS
production or expand cell-death-resis-
tant and -malignant populations through
compensatory proliferation, thereby in-
creasing HCC development. Clearly, in
the hURI-HCC model driven by genotoxic
stress, reducing cell death by p53
deletion predominantly affects premalig-
nant or malignant cells and is likely to
overshadow possible tumor-promoting
effects of cell death in noncancerous
cells.
This study has important implications
for HCC prevention and treatment strate-
gies (Figure 1). However, before consid-
ering NAD+ supplementation as a
possible therapeutic strategy, it would
be helpful to confirm and expand human
data and identify subgroups of HCC pa-778 Cancer Cell 26, December 8, 2014 ª201tients with high URI expression, because
these would likely be the best candidates.
In light of the reported association be-
tween low nicotaminamide and niacin sta-
tus with increased cancer development in
patients (Surjana et al., 2010), the authors’
data showing that NAD+ supplementation
or reduction of hURI expression can pre-
vent HCC and even induce tumor regres-
sion, are of therapeutic interest. However,
it needs to be taken into account that
advanced HCC may become URI-inde-
pendent, as demonstrated by the finding
that turning off hURI overexpression failed
to trigger regression of hURI-driven HCC
at late stages. While primary or secondary
prevention strategies may appear more
promising because they would target
earlier disease stages, they would likely
require extremely long treatment periods
and large patient cohorts to demonstrate
therapeutic effects. Before considering
NAD+ supplementation for therapeutic
purposes, several questions need to be
addressed. Although the authors have
shown reducedNAD+ levels and success-
ful supplementation in a genetic model of
pancreatic cancer, it would be important
to show that NAD+ supplementation re-
duces tumor development in HCCmodels
that are not driven by hURI-overexpres-
sion. Second, previous studies have
suggested NAD+ acts as a component
of tumor-promoting signaling pathways4 Elsevier Inc.(Chiarugi et al., 2012). Hence,
inhibition of the NAD meta-
bolism has been suggested
as a therapeutic concept for
cancer treatment (Chiarugi
et al., 2012). Therefore, thera-
peutic strategies to either
supplement NAD+ or block
its synthesis, e.g., using inhib-
itors of nicotinamide phos-
phoribosyltransferase that
have been suggested for the
treatment of specific forms
of cancer, should be explored
with caution. Future studies
on the restoration of NAD+
pools in patients with liver
cirrhosis or HCC should first
determine the ideal way of
NAD+ administration, with
nicotinamide riboside or
vitamin B3 as possible strate-
gies for supplementation.
Finally, it would be of interest
to understand why URIexpression increases in human cirrhosis
and HCC and whether pathways that in-
crease URI expression could be targeted.
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